Spatial T lymphocyte infiltration into the primary melanoma tumor associates with survival
Tumor infiltrating lymphocyte grade is a prognostic indicator for patients with cutaneous invasive primary melanoma and assigned one of three-levels (brisk, nonbrisk, or absent). We sought to develop objective, quantitative measures of T lymphocyte subtypes spatially within the tumor microenvironment. We applied multiplex whole-slide immunohistochemistry/immunofluorescence to 80 melanomas, using S100 to identify tumor cells (S100+) and CD3 and CD8 to identify noncytotoxic T lymphocytes (CD3+CD8-), cytotoxic CD8+ T lymphocytes (CD3+CD8+), and total T lymphocytes (CD3+CD8- plus CD3+CD8+). We used image analysis to spatially locate the T lymphocyte subtypes within the whole tumor, the tumor center (175 µm into the tumor), and the tumor margin (within 100 µm outside the tumor). T lymphocyte subtypes were quantified for density as CD3+CD8- and CD3+CD8+ cells colocalized with intact nuclei/µm2. Melanoma-specific survival, adjusted for American Joint Committee on Cancer eighth edition stage, improved when a higher density of each T lymphocyte subtype (CD3+CD8-; CD3+CD8+) infiltrated 175 µm into the tumor center or total T lymphocytes infiltrated into the whole tumor (hazard ratios: 0.72-0.77; all P < 0.05). Improved melanoma-specific survival is significantly associated with high density of CD3+CD8- T lymphocytes in the margin after stage adjustment. Our results indicate spatial location of T lymphocyte subset infiltration within the tumor microenvironment is important for predicting melanoma-specific survival.
Authors
- Paul B. Googe (ORCID: https://orcid.org/0000-0002-9185-3548)
- Nancy E. Thomas (ORCID: https://orcid.org/0000-0002-2230-1328)
- Pei Fen Kuan (ORCID: https://orcid.org/0000-0001-7861-916X)
- David L. Corcoran (ORCID: https://orcid.org/0000-0001-7460-9247)
- Yi‐Hsuan Tsai (ORCID: https://orcid.org/0000-0003-2107-4300)
- Eloise Parrish (ORCID: https://orcid.org/0000-0002-9492-4735)
- D. W. Ollila
- Sharon N. Edmiston
- Honglin Hao
- Ronglai Shen
- Kathleen Conway
Institutions
- University of North Carolina at Chapel Hill (US)
- State University of New York (US)
- Memorial Sloan Kettering Cancer Center (US)
- Comprehensive Blood & Cancer Center (US)
- CytomX Therapeutics (United States) (US)
- Stony Brook University (US)
Publication Details
- Journal
- Melanoma Research
- Published
- 2026-07-28
- DOI
- https://doi.org/10.1097/cmr.0000000000001127
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00